Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people.
HIV
Hepatic steatosis
Liver fibrosis
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
15 Apr 2019
15 Apr 2019
Historique:
received:
24
07
2018
accepted:
28
03
2019
entrez:
17
4
2019
pubmed:
17
4
2019
medline:
27
4
2019
Statut:
epublish
Résumé
Hepatic steatosis is prevalent in Western countries, but few studies have evaluated whether the frequency and severity of steatosis are greater in the setting of HIV infection. We compared the prevalence and severity of hepatic steatosis between HIV-infected (HIV+) and uninfected persons and identified factors associated with greater steatosis severity within both groups. We performed a cross-sectional study among participants without cardiovascular disease who participated in a substudy of the Veterans Aging Cohort Study. Hepatic steatosis was defined by noncontrast computed tomography (CT) liver-to-spleen (L/S) attenuation ratio < 1.0. Multivariable linear regression was used to: 1) evaluate the association between HIV infection and severity of hepatic steatosis, as measured by absolute liver attenuation, and 2) identify factors associated with greater severity of steatosis, by HIV status. Among 268 participants (median age, 55 years; 99% male; 79% black; 23% obese; 64% HIV+ [91% on antiretroviral therapy]), the overall prevalence of steatosis was 7.8% and was similar between HIV+ and uninfected individuals (13 [7.6%] versus 8 [8.2%], respectively; p = 0.85). Participants with HIV, the majority of whom received antiretroviral therapy, had a higher mean absolute liver attenuation (mean difference, 5.68 Hounsfield units; p < 0.001), correlating with lesser hepatic steatosis severity, compared to uninfected participants. After adjusting for covariates, only advanced hepatic fibrosis was associated with greater severity of steatosis in HIV+ persons (p = 0.03) and uninfected individuals (p < 0.001). In this sample of participants without cardiovascular disease, the prevalence of hepatic steatosis by noncontrast abdominal CT was not different by HIV status. Increasing severity of steatosis was independently associated with advanced hepatic fibrosis in both groups.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatic steatosis is prevalent in Western countries, but few studies have evaluated whether the frequency and severity of steatosis are greater in the setting of HIV infection. We compared the prevalence and severity of hepatic steatosis between HIV-infected (HIV+) and uninfected persons and identified factors associated with greater steatosis severity within both groups.
METHODS
METHODS
We performed a cross-sectional study among participants without cardiovascular disease who participated in a substudy of the Veterans Aging Cohort Study. Hepatic steatosis was defined by noncontrast computed tomography (CT) liver-to-spleen (L/S) attenuation ratio < 1.0. Multivariable linear regression was used to: 1) evaluate the association between HIV infection and severity of hepatic steatosis, as measured by absolute liver attenuation, and 2) identify factors associated with greater severity of steatosis, by HIV status.
RESULTS
RESULTS
Among 268 participants (median age, 55 years; 99% male; 79% black; 23% obese; 64% HIV+ [91% on antiretroviral therapy]), the overall prevalence of steatosis was 7.8% and was similar between HIV+ and uninfected individuals (13 [7.6%] versus 8 [8.2%], respectively; p = 0.85). Participants with HIV, the majority of whom received antiretroviral therapy, had a higher mean absolute liver attenuation (mean difference, 5.68 Hounsfield units; p < 0.001), correlating with lesser hepatic steatosis severity, compared to uninfected participants. After adjusting for covariates, only advanced hepatic fibrosis was associated with greater severity of steatosis in HIV+ persons (p = 0.03) and uninfected individuals (p < 0.001).
CONCLUSIONS
CONCLUSIONS
In this sample of participants without cardiovascular disease, the prevalence of hepatic steatosis by noncontrast abdominal CT was not different by HIV status. Increasing severity of steatosis was independently associated with advanced hepatic fibrosis in both groups.
Identifiants
pubmed: 30987601
doi: 10.1186/s12876-019-0969-1
pii: 10.1186/s12876-019-0969-1
pmc: PMC6466708
doi:
Types de publication
Comparative Study
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
52Subventions
Organisme : NHLBI NIH HHS
ID : K01 HL134147
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA206465
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01AA013566
Pays : United States
Références
Clin Infect Dis. 2001 Feb 1;32(3):492-7
pubmed: 11170959
Gastroenterology. 2005 Jun;128(7):1898-906
pubmed: 15940625
Hepatology. 2005 Aug;42(2):310-6
pubmed: 16025515
J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):557-61
pubmed: 16044007
Clin Infect Dis. 2006 Mar 15;42(6):836-42
pubmed: 16477562
Radiology. 2006 Apr;239(1):105-12
pubmed: 16484355
J Hepatol. 2006 Jun;44(6):1026-32
pubmed: 16618518
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
Med Care. 2006 Aug;44(8 Suppl 2):S13-24
pubmed: 16849964
Am J Manag Care. 2006 Oct;12(10):597-606
pubmed: 17026414
AJR Am J Roentgenol. 2007 May;188(5):1307-12
pubmed: 17449775
Aliment Pharmacol Ther. 2007 Dec;26(11-12):1489-98
pubmed: 17903235
J Gastroenterol Hepatol. 2008 Jun;23(6):900-7
pubmed: 17995942
Clin Gastroenterol Hepatol. 2009 Apr;7(4):481-6
pubmed: 19162235
Hepatology. 2009 Mar;49(3):1017-44
pubmed: 19243014
Aliment Pharmacol Ther. 2009 Jul;30(1):61-70
pubmed: 19292832
AIDS. 2009 Jun 19;23(10):1227-34
pubmed: 19444074
Ann Hepatol. 2009 Oct-Dec;8(4):346-52
pubmed: 20009134
Int J Obes (Lond). 2010 May;34(5):791-9
pubmed: 20125098
PLoS One. 2010 Apr 09;5(4):e10106
pubmed: 20419086
Eur Radiol. 2011 Jan;21(1):87-97
pubmed: 20680289
Radiology. 2011 Mar;258(3):760-6
pubmed: 21212369
HIV Med. 2011 Sep;12(8):463-71
pubmed: 21251186
Dig Dis Sci. 2011 Jul;56(7):2145-51
pubmed: 21318585
Hepatology. 2011 May;53(5):1504-14
pubmed: 21400557
Curr Opin Infect Dis. 2012 Feb;25(1):10-6
pubmed: 22183113
Acad Radiol. 2012 Jul;19(7):811-8
pubmed: 22521729
Antivir Ther. 2012;17(7):1281-9
pubmed: 22951353
Infection. 2013 Apr;41(2):425-9
pubmed: 23225268
AIDS Rev. 2013 Jan-Mar;15(1):25-31
pubmed: 23449226
Ann Hepatol. 2013 Sep-Oct;12(5):740-8
pubmed: 24018492
Am J Gastroenterol. 2014 May;109(5):695-704
pubmed: 24642579
Lancet. 2014 Jul 19;384(9939):241-8
pubmed: 25042234
PLoS One. 2015 Feb 10;10(2):e0117813
pubmed: 25668620
J Hepatol. 2015 Aug;63(2):470-6
pubmed: 25776891
JAMA. 2015 Jun 9;313(22):2263-73
pubmed: 26057287
Clin Gastroenterol Hepatol. 2016 Feb;14(2):301-8.e1-2
pubmed: 26291667
AIDS Res Hum Retroviruses. 2016 Jan;32(1):50-8
pubmed: 26352511
PLoS One. 2016 Jan 26;11(1):e0147879
pubmed: 26812065
Dig Dis Sci. 2016 May;61(5):1337-47
pubmed: 26848588
J Am Coll Cardiol. 2016 Apr 26;67(16):1965-6
pubmed: 27102512
Aliment Pharmacol Ther. 2016 Aug;44(4):411-21
pubmed: 27301337
Drug Alcohol Depend. 2016 Nov 01;168:196-202
pubmed: 27694059
Hepatology. 2017 Mar;65(3):853-863
pubmed: 27981599
Hepatology. 2017 Nov;66(5):1486-1501
pubmed: 28586172
JAMA. 2018 Jul 24;320(4):379-396
pubmed: 30043070
Demography. 1995 Aug;32(3):459-70
pubmed: 8829977